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 CURRENTOPINION The tuberculosis-associated immune reconstitution
inflammatory syndrome: recent advances in clinical
and pathogenesis research
Naomi F. Walkera, Cari Stekb,c,d, Sean Wassermanb,d,
Robert J. Wilkinsonb,d,e,f, and Graeme Meintjesb,d
Purpose of review
Antiretroviral therapy (ART) is an essential, life-saving intervention for HIV infection. However, ART initiation is
frequently complicated by the tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) in
TB endemic settings. Here, we summarize the current understanding highlighting the recent evidence.
Recent findings
The incidence of paradoxical TB-IRIS is estimated at 18% (95% CI 16–21%), higher than previously
reported and may be over 50% in high-risk groups. Early ART initiation in TB patients increases TB-IRIS risk
by greater than two-fold, but is critical in TB patients with CD4 counts less than 50cells/ml because it
improves survival. There remains no validated diagnostic test for TB-IRIS, and biomarkers recently proposed
are not routinely used. Prednisone initiated alongside ART in selected patients with CD4 less than
100 cells/ml reduced the risk of paradoxical TB-IRIS by 30% in a recent randomized-controlled trial (RCT)
and was not associated with significant adverse effects. Effective also for treating paradoxical TB-IRIS,
corticosteroids remain the only therapeutic intervention for TB-IRIS supported by RCT trial data. TB-IRIS
pathogenesis studies implicate high antigen burden, innate immune cell cytotoxicity, inflammasome
activation and dysregulated matrix metalloproteinases in the development of the condition.
Summary
Specific biomarkers would aid in identifying high-risk patients for interventions and a diagnostic test is
needed. Clinicians should consider prednisone for TB-IRIS prevention in selected patients. Future research
should focus on improving diagnosis and investigating novel therapeutic interventions, especially for
patients in whom corticosteroid therapy is contraindicated.
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INTRODUCTION
HIV-associated TB is common, with an estimated
1.4 million cases and 374000 deaths annually [1].
In parts of sub-Saharan Africa, around 60% of TB
patientsareHIVcoinfected [1].Antiretroviral therapy
(ART) is an essential, life-saving intervention forHIV,
butHIV-infectedpatients startingARTare athigh risk
of tuberculosis-associated immune reconstitution
inflammatory syndrome (TB-IRIS) in TB endemic
settings. TB-IRIS is an acute inflammatory condition
that presents with worsening, or development of
new, tuberculosis disease in a patient already on TB
treatment after starting ART (paradoxical TB-IRIS), or
a new diagnosis of TB with a particularly acute,
inflammatory presentation after starting ART
(unmasking TB-IRIS). Rapid restoration of immunity
after ART, with exaggerated inflammatory responses
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REVIEW
to Mycobacterium tuberculosis (Mtb) antigens, under-
lies this condition although the pathophysiology is
incompletely understood.
In a systematic review, Namale et al. [2] collated
studies published before 3 May 2014 reporting inci-
dence, clinical features, management and outcomes
of paradoxical TB-IRIS, including 40 studies, 7789
patients at risk and 1048 TB-IRIS cases. Studies were
from Africa, Asia, Europe, North and South America.
Here, we discuss key findings in subsequently pub-
lished literature, on TB-IRIS epidemiology, out-
comes, management, prevention, diagnosis and
pathogenesis. We focus on paradoxical TB-IRIS,
the most common form of HIV-associated IRIS
and most frequently studied. Unmasking TB-IRIS
is discussed in a separate section. Knowledge to date,
with reference to key review articles and recent
original research articles, is summarized in Table 1
[2,3&,4–6,7&,8,9,10&,11,12&&].
KEY POINTS
 The incidence of paradoxical TB-IRIS is estimated at
18% (95% CI 16–21%) and may be over 50% in
high-risk groups.
 A specific diagnostic test for TB-IRIS is lacking and
diagnosis remains a major challenge, especially in
low-resource settings.
 Prednisone initiated alongside ART in patients with
CD4 count less than 100 cells/ml reduced the risk of
paradoxical TB-IRIS by 30% in a recent RCT, offering
a preventive strategy for selected patients.
 High antigen burden and innate immune mechanisms,
including cytotoxic activity, inflammasome activation
and matrix metalloproteinases, appear to contribute to
TB-IRIS pathogenesis.
Table 1. Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome – knowledge summary
Knowledge summary Key references
Incidence Adults overall: 18% (95% CI 16–21%), with a range of 4–54%; higher rates
in patients with lower CD4 counts (up to 57% in patients with CD4 count
<200 cells/ml).
Reviewed in [2]
Recent cohort described
in [3&]
South African children: 6.7% reported in a recent prospective study [4]
Risk factors Low CD4 count at ART initiation;
High HIV viral load at ART initiation
Reviewed in [2]
Shorter time between TB treatment initiation and ART initiation Meta-analyses reported
in [5,6]
Disseminated TB/high mycobacterial load. [3&,7&]
Clinical presentation Systemic, pulmonary and lymph node presentations most common Reviewed in [2]
In a recent study, median days to symptom onset reported as 6 (range 1–23) [3&]
Mortality All-cause mortality rate of 7% (95% CI 4–11%) and IRIS-attributable deaths of
2% (95% CI 1–3%)
Reviewed in [2]
Higher mortality in CNS TB-IRIS Reviewed in [8]
Pathogenesis Innate immune cell activation, including neutrophils, monocytes and NK cells;
Antigen-specific upregulation of cytotoxic mediators
Inflammasome activation;
Hypercytokinaemia (including IL-1b, IL-6 and TNF-a) and MMP upregulation/
secretion
Reviewed in [9]; see
also, [3&,7&,10&]
Treatment Prednisone (1.5 mg/kg for 2 weeks followed by 0.75 mg/kg for 2 weeks) for
treatment of paradoxical TB-IRIS reduced length of hospital admission and
number of therapeutic procedures required, and improved symptoms in
paradoxical TB-IRIS
Randomized-controlled
trial reported in [11]
Consensus is not to stop ART, but to investigate fully for alternative causes, and
provide symptomatic treatment
Reviewed in [9]
Prevention Prednisone (40mg daily for 2 weeks, followed by 20mg daily for 2 weeks)
from ART initiation reduces the risk of future paradoxical TB-IRIS by 30%
[12&&]
Do not delay ART initiation beyond 2 weeks after TB treatment initiation in
patients with CD4 count <50 cells/mm3, unless CNS TB diagnosed (then
delay 4–8 weeks). Early ART improves survival in patients with CD4<50
cells/mm3 even though it increases TB-IRIS risk > two-fold
Meta-analyses reported
in [5,6]
The tuberculosis-associated immune reconstitution inflammatory syndrome Walker et al.
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DEFINITIONS
As there are no validated diagnostic tests for TB-IRIS,
diagnosis is clinical. The International Network for
the Study of HIV-associated IRIS (INSHI) consensus
definitions of paradoxical and unmasking TB-IRIS
are the most commonly used and have been vali-
dated [13,14]. The Aids Clinical Trials Group defini-
tion (see https://actgnetwork.org/IRIS_Case_
Definitions) and IMPAACT trial definition (see
https://www.impaactnetwork.org for Adolescent
and Paediatric cohorts) have been used in research
settings. The schematic in Fig. 1 summarizes the
different terms used and the relationship to TB treat-
ment and ART initiation. The case definitions pro-
vide subclassification into confirmed and probable
paradoxical TB-IRIS according to the extent in which
other possible causes of symptoms have been ade-
quately excluded. ART-associated TB is a broad term
that encompasses new TB diagnoses in patients who
have recently commenced ART, including unmask-
ing TB-IRIS, with the recognition that new TB diag-
noses are frequently made in patients who have
recently commenced ART but not all have the fea-
tures of unmasking IRIS [13]. Two illustrative cases of
paradoxical TB-IRIS cases are presented in Fig. 2.
PARADOXICAL TUBERCULOSIS-
ASSOCIATED IMMUNE RECONSTITUTION
INFLAMMATORY SYNDROME
Incidence and risk factors
Recently reported cohort studies of adult patients in
Africa and India have demonstrated high TB-IRIS
incidence rates (19–57%) with the highest rates in
patients with low CD4 counts [3
&
,15–17]. A study of
HIV-infected and HIV-uninfected patients with TB
meningitis in India reported paradoxical reactions
in 11 of 13 (84.6%) HIV-infected patients, but did
not report on the temporal relationship to ART
initiation [18]. A recent cohort study of 104 South
African children was the first to prospectively study
paradoxical TB-IRIS in children concluding that the
incidence of paradoxical TB-IRIS in children was
Untreated HIV Untreated HIV, new TB diagnosis
START 
EFFECTIVE
ART
Heightened intensity of 
TB presentation with 
component
Unmasking 
TB-IRIS
New TB diagnosis:
ART-associated TB
Screening for TB:
no TB found
START EFFECTIVE
TB TREATMENT
START 
EFFECTIVE
ART
Paradoxical TB-IRIS
Clinical Deterioration 
Consider other causes of 
clinical deterioration
- drug resistance
- non-adherence
- drug toxicity
- other new OI
At least one major criterion 
or
 two minor clinical criteria required*
Time
3 months
FIGURE 1. Definitions of TB-IRIS. Adapted from INSHI definition. TB-IRIS can also occur when ART is reinitiated after stopping
ART and when changing from a failing regiment to a new effective ART regimen. ART, antiretroviral therapy. Major criteria
for paradoxical TB-IRIS: (i) new/enlarging LN, cold abscess or other focal tissue involvement; (ii) new/worsening radiological
features of TB; (iii) new or worsening central nervous system tuberculosis; (iv) new or worsening serositis. Minor criteria for
paradoxical TB-IRIS: (i) new/worsening constitutional symptoms; (ii) new/worsening respiratory symptoms; (iii) new/worsening
abdominal pain and peritonitis/hepatomegaly/splenomegaly/abdominal adenopathy.
Tuberculosis and HIV
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low. Paradoxical TB-IRIS occurred in 7 of 104 (6.7%)
children studied [4]. A recent trial of urgent (<48h)
versus poststabilization (7–14 days) ART initiation
in hospitalized children in Kenya reported IRIS inci-
dence as a primary outcome measure, using
IMPAACT definitions of IRIS. A total of 27 of 179
children had a diagnosis of suspected TB at enrol-
ment and nine children were on TB treatment at
enrolment. Eighteen patients had suspected TB-IRIS
during 6 months follow up, although it is not stated
whether these were unmasking or paradoxical TB-
IRIS [19].
Baseline low CD4 count and high HIV viral load
have been associated with an increased risk of TB-
IRIS in prospective studies, including randomized
controlled trials (RCTs) evaluating the optimal time
for ART initiation in HIV [2]. The most recently
published was a study of 478 patients in Ethiopia,
starting ART at 1, 4 or 8 weeks of TB treatment,
powered for mortality outcome at 48 weeks. No
ART initiation TB-IRIS
ART initiation TB-IRIS
(a)
(b)
FIGURE 2. Paradoxical TB-IRIS case illustrations. Patient (a) was a 29-year-old man, with a CD4 count of 14 cells/ml, who
had been on TB treatment for 1 month. He complained of loss of appetite, 4 kg weight loss and recurrence of cough and chest
pain 2 weeks after starting ART. Chest radiograph shows extension of the left hilar infiltrate. His C-reactive protein had
increased from 11mg/l before the start of ART to 292mg/l. His symptoms spontaneously resolved 2 weeks later. Patient (b)
was a 36-year-old man, with a CD4 count of 73 cells/ml, who had been on TB treatment for 3 weeks. One week after starting
ART, he complained about poor appetite, gradually worsening with dyspnoea, cough, night sweats, diarrhoea, vomiting and
fatigue. He was tachypnoeic, with a temperature of 388C. Chest radiograph showed an increase in hilar and paratracheal
lymphadenopathy. His C-reactive protein had increased from 4mg/l before the start of ART to 120mg/l. He was started on
prednisone treatment, resulting in complete resolution of his symptoms over the next few weeks.
The tuberculosis-associated immune reconstitution inflammatory syndrome Walker et al.
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survival benefit was evident with ART initiation at
week 1 and TB-IRIS was more frequent in patients
with early versus later ART initiation, with an inci-
dence of 15 (95% CI 9–24), 5 (95% CI 2.3–11.7) and
0 per 100 person years in those who commenced
ART at 1, 4 and 8weeks, respectively (P¼0.001) [20].
Two meta-analyses of RCTs on the optimal time
to initiate ART following commencement of TB
treatment in HIV-associated TB have reported com-
bined relative risks of TB-IRIS of 2.19 (95% CI 1.77–
2.70) and 2.31 (95% CI 1.87–2.86) for early (up to 4
weeks) versus late (8–12 weeks) ART initiation [5,6].
In patients with a CD4 count below 50 cells/mm3, a
mortality benefit was apparent with early ART,
favouring ART initiation within 2 weeks following
TB treatment in such patients. However, a relatively
high incidence of TB-IRIS can be expected in these
patients who commence ART at 2 weeks of antitu-
berculous therapy – the risk was elevated over two-
fold with early ART.
Our cohort study followed 47 TB patients (with
baseline CD4<200 cells/ml) commencing ART,
investigating immunopathology caused by matrix
metalloproteinases [3
&
]. The incidence of paradoxi-
cal TB-IRIS was 57%. Patients who went on to
develop TB-IRIS had higher plasma MMP-8 and
procollagen III N-terminal propeptide (PIIINP, a
matrix degradation product released during colla-
gen turnover) and evidence of an increased systemic
inflammatory response (higher heart rates and
higher respiratory rates) but lower lymphocyte
counts, at TB diagnosis, compared to those who
did not develop TB-IRIS. Urine lipoarabinomannan
(LAM, a marker of renal TB indicating disseminated
infection in patients with advanced HIV) was more
often positive in TB-IRIS patients (adjusted odds
ratio¼10.9). Marais et al. [7&] reported increased
proportions of cerebrospinal fluid (CSF) culture pos-
itivity and persistently positive CSF cultures in
patients who developed TBM-IRIS relative to those
who did not. However, a recent study of 90 patients
with baseline CD4 count less than 250 cells/mm3,
starting ART, nested within an RCT of early versus
late ART, did not find an association between posi-
tive blood cultures for TB and TB IRIS diagnosis [21].
The question of whether integrase inhibitors
increase the risk of paradoxical TB-IRIS as they result
in a more rapid decline in HIV viral load has arisen
with increasing use of integrase inhibitors in first-
line ART regimens. Observational studies have
reported an association with all-cause IRIS [22,23].
A recent meta-analysis addressing Dolutegravir use
did not find an association with IRIS [24]. Clinical
trials have not demonstrated an increased risk of TB-
IRIS [25,26]. This question is being further addressed
in ongoing trials.
In summary, paradoxical TB-IRIS frequently
complicates ART initiation in HIV-associated TB,
with a high incidence in selected patients. More
advanced immunosuppression, more inflammatory
TB presentation, disseminated TB and persistent
culture positivity, and a shorter time to ART initia-
tion from TB treatment have all been associated
with increased TB-IRIS risk and together suggest that
increased mycobacterial burden permitted by
advanced immunosuppression is causally associated
with the development of TB-IRIS.
Outcomes
Overallmortality fromparadoxicalTB-IRISappears to
be relatively low but may be confounded by under-
diagnosis and lack of reporting [2]. Recent cohort
studies have reported few or no deaths due to TB-
IRIS. The most recently published RCT of timing of
ART initiation in TB patients reported only one TB-
IRIS case among 64 deaths [20]. However, in a pooled
analysis of RCTs that reported TB-IRIS events, the
estimated relative risk of death from paradoxical TB-
IRIS in early ART arms versus late armswas 6.94 (95%
CI 1.26–38.22)with an event rate of 0.78% (9 of 1153
cases) in the early arms versus 0 of 1119 in the late
arms [5]. Central nervous system TB-IRIS carries a
particularly high mortality risk, up to 30% [7
&
,8]. In
our cohort study of 47 patients, hospital admission
was required in 13 of 29 (45%) TB-IRIS patients
compared to 1 of 18 (6%) non-IRIS controls
(P¼0.007) [3&]. There were no deaths from TB-IRIS
in this study, performed in an experienced research
centre with close clinical monitoring.
Diagnostic and prognostic biomarkers
In a prospective observational study of 170 TB
patients with CD4 counts less than 125 cells/ml,
starting ART in Botswana, 33 (19%) patients devel-
oped paradoxical TB-IRIS and 18 (11%) patients
died, but there was only one (3%) death among
TB-IRIS patients, reported as occurring after the
resolution of TB-IRIS symptoms [17]. This study
evaluated 26 biomarkers in plasma by Luminex,
in baseline pre-ART samples with respect to an
eventual diagnosis of paradoxical TB-IRIS or death.
Lower growth factor and Th1 cytokine responses,
and lower concentrations of the proinflammatory
cytokine interleukin-17 (IL-17) were associated with
TB-IRIS, whereas higher baseline proinflammatory
cytokines, tumour necrosis factor-a (TNF-a) and
interleukin-6, in addition to MCP-1 and EOTAXIN,
were associated with death, suggesting different
pathophysiological mechanisms leading to TB-IRIS
and early mortality due to TB, following ART
initiation.
Tuberculosis and HIV
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A study of 267 patients nested within the CADI-
RIS trial evaluated 20 biomarkers at ART baseline to
investigate an association with all-cause IRIS [27].
There were 62 IRIS cases diagnosed using ACTG
definitions, of which 19 (34%) were TB-IRIS (14
paradoxical, five unmasking). TB-IRIS was associ-
ated with a distinct biosignature comprising ele-
vated C-reactive protein, soluble CD14 and
interferon-g (IFN-g) and lower haemoglobin. These
factors were combined into a score that allowed
prediction of TB-IRIS versus no-IRIS with a sensitiv-
ity of 71.4% (0.52–88.7) and a specificity of 73.2%
(57.1–85.9).
AMalaysian study comparing a combined group
of patients with paradoxical and unmasking TB-IRIS
(n¼15) to controls with TB but no IRIS (n¼14) and
those without TB or IRIS (n¼15), using INSHI def-
initions, found elevated IL-18 and CXCL-10 levels
prior to ART to be predictive of TB-IRIS [28]. In a
validation cohort in India, baseline IL-18 predicted
paradoxical TB-IRIS with an AUC¼0.742, P¼0.004
(no confidence intervals reported) [28]. One study
investigated the predictive value of antigen-specific
cytokine responses for TB-IRIS prediction and found
it to be of little value [29].
Management
Management of paradoxical TB-IRIS includes inves-
tigations to rule out other diagnoses (e.g. sepsis),
supportive management (e.g. IV fluids for hypoten-
sion), symptomatic treatment (e.g. analgesia and
antiemetics), surgical or percutaneous interventions
(e.g. abscess drainage) and inhibition of excessive
immune responses (corticosteroids). It is critical to
exclude drug-resistant TB, which is an important
cause of clinical deterioration in HIV-associated TB,
and which can manifest with TB-IRIS features that
are clinically indistinguishable from IRIS seen
in drug-sensitive TB [30]. ART interruption is not
recommended.
Corticosteroids remain the only treatment for
paradoxical TB-IRIS whose use is supported by RCT
data [11]. Other immunomodulatory therapies have
been the explored in case reports and case series
including several reports of anti-TNF-a therapy, and
one report of intravitreal anti-VEGF (Bevacivumab)
therapy in ocular TB-IRIS [31–34]. Prednisone is not
licensed for the treatment of TB-IRIS and other
immunotherapies are investigational.
Prevention
Two double-blind randomized, placebo-controlled
studies have assessed strategies to prevent TB-IRIS in
adults. The CADIRIS study assessed the efficacy of
the CCR5 blocker maraviroc in reducing all-cause
IRIS, including TB-IRIS, in patients with CD4 count
less than 100 cells/ml [35]. Time to an IRIS event by
24 weeks was the primary outcome. No difference in
proportion of TB-IRIS was found between the mar-
aviroc and the placebo arm.
The PredART trial assessed the efficacy and
safety of prophylactic prednisone in preventing
TB-IRIS in patients who were identified as being at
high risk for paradoxical TB-IRIS [12
&&
]. Inclusion
criteria included CD4 count less than 100 cells/ml,
microbiologically confirmed TB or clinical diagnosis
with symptomatic response to antituberculosis
treatment, and starting ART within 30 days after
starting antituberculosis treatment [12
&&
]. Exclusion
criteria included Kaposi’s sarcoma, neurological or
pericardial tuberculosis, rifampicin-resistant tuber-
culosis and hepatitis B surface antigen positivity.
The primary endpoint was the development of par-
adoxical TB-IRIS (according to the INSHI consensus
definition) within 12 weeks after starting ART adju-
dicated by an independent committee. Two hun-
dred and forty participants were randomized 1 : 1 to
receive either prednisone (40mg daily for 2 weeks,
followed by 20mg daily for 2 weeks) or identical
placebo within 48h of starting ART. Prophylactic
prednisone reduced the risk of paradoxical TB-IRIS
by 30% (56 of 120 in the placebo arm versus 39 of
120 in the prednisone arm), corresponding with an
absolute reduction in incidence of 14.2%.
Prednisone was safe, with no statistically signifi-
cant difference in grade 4 adverse events, severe
infections, malignancies, death, corticosteroids
side-effects or immunological and virological out-
comes at week 12, between the prednisone and the
placebo arm. There did not appear to be ‘break-
through cases’ when the 28-day course of prednisone
was stopped. Prednisone also reduced the incidence
of more severe TB-IRIS, judged from the number of
patients with TB-IRIS fulfilling at least one INSHI
major criterion or prescribed prednisone treatment
of TB-IRIS; proportions for both of these secondary
outcomes were also reduced in the prednisone arm.
Further study is required to conclude whether
prednisone would benefit patients not included by
the enrolment criteria. Prednisone is neither licensed
for treatment nor prevention of TB-IRIS. However,
based on this result, we recommend that preventive
treatment with prednisone, at the doses above, for
HIV-infected TB patients with a CD4 nadir less than
100cells/ml, who have had hepatitis B and Kaposi’s
sarcomaexcluded,whoarenotdiagnosedwith rifam-
picin-resistant TB and who are symptomatically
improving on TB treatment prior to ART. A similar
recommendation has been included in the 2017
European AIDS Clinical Society guidelines [36].
The tuberculosis-associated immune reconstitution inflammatory syndrome Walker et al.
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Pathogenesis
Recent evidence has implicated exaggerated cyto-
toxic responses, excessive proinflammatory innate
immune responsesmediated by inflammasome acti-
vation and MMP-driven tissue damage in TB-IRIS
pathogenesis. These processes are likely to be inter-
related. A detailed review of the pathogenesis of TB-
IRIS is beyond the scope of this review. However,
here we detail key recent studies that have enhanced
our understanding.
We investigated transcription profiles of Mtb-
stimulated peripheral blood mononuclear cells of
TB-IRIS and controls who did not develop TB-IRIS,
finding cytotoxic mediators perforin and granzyme
B to be among the top differentially regulated genes
[37]. Correspondingly granzyme B was increased
in serum of TB-IRIS patients but reduced in pre-
dnisone-treated patients. We found elevated
CD3þVa24þ cell populations in TB-IRIS patients
suggesting that natural killer T cells may play a role
in TB-IRIS. A previous report found that increased
natural killer (NK) cell degranulation predicted TB-
IRIS and together these studies support a role for
aberrant cytotoxic responses [38]. Further studies
exploring the clinical implications of these findings
are required.
Lai et al. [39] performed transcriptomic analysis
of whole blood from 17 TB-IRIS patients and 15 non-
IRIS controls in a longitudinal study, pre-ART, at 0.5
weeks post-ART initiation and at 2 weeks post-ART
initiation (time of IRIS onset). The early pre-IRIS
transcriptomic signature on ART in patients who
developed TB-IRIS was enriched for genes associated
with innate immunity, including the JAK family of
kinases involved in IL-6 signalling pathways, inter-
feron signalling, pattern recognition receptors and
macrophage function. At the time of TB-IRIS onset,
TLR receptor, TREM-1 signalling and the role of
pattern recognition receptors in recognition of bac-
teria and viruses were among the most upregulated
pathways indicating innate immune function to be
at the centre of divergent immune responses. This
was validated by plasma measurement of cytokines
at the time of TB-IRIS onset: IL-12p40, IL-6, TNF-a
and IFN-g were found to be significantly increased
compared to non-IRIS controls. Increased IL-1b, IL-
1a, caspase-1 and caspase-5 secretion from heat-
killed H37Rv Mtb-stimulated PBMC from TB-IRIS
patients compared to non-IRIS controls suggested
increased inflammasome activation in TB-IRIS.
Excessive MMP activity is implicated in inflam-
matory disease in TB-IRIS and may be corticosteroid
modulated [40]. In our recent study, plasma MMP-8
(neutrophil collagenase) was most significantly ele-
vated in TB-IRIS patients, at TB diagnosis and at the
time of TB-IRIS onset, compared to controls [3
&
].
Plasma MMP-8 correlated with peripheral blood
neutrophil count, suggesting that it may be neutro-
phil-derived. PIIINP was elevated in TB-IRIS patients
at TB diagnosis and at the time of TB-IRIS. The
previously described Botswanan cohort study found
increases in plasma MMP-8 on ART to be associated
with TB-IRIS, and abnormal pulmonary function
following TB treatment, although intervention
studies are required to prove a causal link [16].
Neutrophils are elevated, activated and found at
the site of caseous necrosis in human TB-IRIS [10
&
].
In transcriptional analysis of unstimulated PBMC
from TB-IRIS patients, the most upregulated tran-
scripts in TB-IRIS patients versus controls implicated
increased neutrophil activity (S100A9, NLRP12,
COX-1 and IL-10), and this was supported by ele-
vated neutrophil elastase and human neutrophil
peptides 1–3 in plasma of TB-IRIS patients. These
data suggest that neutrophil influx to the site of
disease, activation and early cell death occur in TB-
IRIS patients leading to local necrosis and tissue
destruction.
In the context of advanced HIV-1 andMtb infec-
tion, impaired Mtb antigen presentation by antigen
presenting cells may permit excessive mycobacterial
replication pre-ART. This may be contributed to by
direct effects of the HIV-1 virus and poor T-cell help.
Differential recovery of T-cell subsets, particularly
with respect to activationandmemorycell responses,
has been associated with TB-IRIS [41,42]. However,
the studies described above highlight the critical role
for early innate immune responses in the excessive
inflammation underlying TB-IRIS. Inflammasome
activation and MMP activity are potential targets
for future host-directed therapies.
UNMASKING TUBERCULOSIS-
ASSOCIATED IMMUNE RECONSTITUTION
INFLAMMATORY SYNDROME
Although ART has a major impact on reducing the
risk of TB in HIV-infected individuals, TB remains
the most frequently diagnosed opportunistic infec-
tion after ART initiation, particularly in high TB
burden settings. The risk of developing TB is highest
within the first 3 months after starting ART [43].
There may be delayed immune recovery after initia-
tion of ART, increasing the period of high risk for
HIV-associated TB. In addition, there may be sub-
clinical TB (sputum culture positivity in asymptom-
atic individuals), prevalent in resource-limited
settings such as sub-Saharan Africa where current
screening tools perform suboptimally for active case
finding [44,45]. Thus, a substantial number of
patients, and particularly those withmore advanced
immunodeficiency, are at high risk for active TB
Tuberculosis and HIV
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after the initiation of ART because of both failure of
diagnosis of prevalent TB prior to starting ART and
ongoing persistent immune defects. The diagnosis
of ‘unmasking TB-IRIS’ is reserved for a subgroup of
patients with ART-associated TB who manifest an
acute inflammatory form of TB following ART initi-
ation (see Fig. 1 and definitions given above) [46].
In the absence of specific diagnostic tests and a
robust clinical case definition to distinguish
unmasking TB-IRIS from other forms of ART-associ-
ated TB, there are limited published data on its
clinical manifestations. The reported incidence of
unmasking TB-IRIS in South Africa and Uganda
ranges between 1 and 6% [47–50]. In a large
prospective study in Kwazulu-Natal, South Africa,
unmasking TB-IRIS occurred in 19 out of 498 (3.8%)
patients at a median of 12 days (IQR 7–49) after
initiating ART [48]. This timing is consistent with
other studies, where the onset has ranged between 4
and 79 days [47,51]. The clinical phenotype has
been most frequently characterized by lymphadeni-
tis, abscess formation (including in the central ner-
vous system), serositis and pulmonary infiltration
[47,50,51]. In the Kwazulu-Natal cohort, 3 of 25
(12%) deaths and 7 of 65 (11%) hospitalizations
were attributed to unmasking TB-IRIS [48]. Risk
factors identified for unmasking TB-IRIS include
more advanced immunosuppression, a more pro-
nounced response to ART (greater decline in HIV
viral load and larger increase in CD4 cells), intratho-
racic adenopathy on pre-ART chest radiograph,
anaemia, weight loss, low BMI and elevated C-reac-
tive protein [47,48,51].
Investigations to confirm the diagnosis of TB
should be undertaken in all cases of suspected ART-
associatedTB, includingdrug susceptibility testing. It
is important to exclude other causes of clinical dete-
rioration on ART, such as other opportunistic infec-
tions and malignancies, and adverse drug reactions.
There is no specific therapeutic intervention for
unmasking TB-IRIS, but continuing ART, providing
symptomatic treatments alongside antituberculous
therapyandmanaging complications are key toman-
agement [51]. Paradoxical reactions may complicate
the clinical course of patients with unmasking TB-
IRIS after they have commenced TB treatment [52].
The routine use of corticosteroids is not recom-
mended, but sometimes corticosteroids are used if
there are severe inflammatory manifestations. There
is no clinical trial evidence to support this strategy.
Despite having similar clinical presentations,
there is some suggestion that the immunopathology
associated with unmasking TB-IRIS may differ from
the better-characterized paradoxical form. In one
recent study, transcriptomic profiling of TST biop-
sies from three patients with unmasking TB-IRIS
showed increased expression of genes in the Th2
pathway compared to both HIV-negative and HIV-
positive controls without TB-IRIS. These findings
were supported by increased transcriptional expres-
sion and immunostaining of interferon regulatory
factor 4, which has been associated with Th2
responses [53]. Similarly to paradoxical TB-IRIS
where the primacy of Th1 responses has been ques-
tioned, another study reporting a well-characterized
patient with unmasking TB-IRIS showed that tuber-
culin-specific Th1 responses became expanded only
after resolution of IRIS symptoms, and that there
was a distorted balance of T-cell phenotypes favour-
ing the central memory T-cell compartment prior to
IRIS onset [54]. The role of innate immune effectors,
including NK cells, in the pathogenesis of unmask-
ing TB-IRIS has also been highlighted [55]. Addi-
tional investigations into the immunological
mechanisms are needed, particularly with regard
to the role of the innate immune response and
the inflammasome, to identify potential predictors
and therapeutic targets for unmasking TB-IRIS [9].
FUTURE DIRECTIONS
Major insights into TB-IRIS pathogenesis have come
from human observational studies with ex-vivo
analysis of immune parameters. An appropriate ani-
mal model has been lacking, although a mouse
model of MAI IRIS has been used [56]. A macaque
SIV-Mtb coinfection model using detailed PET-CT
imaging to study early immunological changes in
the lung is providing useful pathophysiological
insights into early HIV-TB coinfection events
[57,58]. This model could in future aid in the study
of TB-IRIS, particularly in attributing causality to
immune mediators and pathways associated with
TB-IRIS in human studies. TB-IRIS pathogenesis
studies have identified multiple targets for which
biological modulators exist. There is a rationale for
moving more candidates to human experimental
medicine studies and early-stage clinical trials. Even
where an interventional study does not show a
positive outcome, the pathophysiological insights
provided may be extremely valuable. Strategies for
future evaluation also include the use of higher
doses of corticosteroids for prevention and the use
of biomarkers to target preventive and treatment
strategies at those most likely to benefit.
CONCLUSION
TB-IRIS causes significant morbidity in resource-
limited settings, and mortality risk may be under-
estimated. A sensitive and specific diagnostic test
is lacking, but would be extremely valuable.
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Biomarkers of risk could aid in identifying high-risk
patients for interventions. Clinicians should
consider prednisone for TB-IRIS prevention in
selected patients. Future research should focus on
improving diagnosis and investigating novel
therapeutic interventions.
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